GPR3 and GPR6, novel molecular targets for cannabidiol

Biochemical and Biophysical Research Communications

Volumn 490, Issue 1, 2017, Pages 17-21

  Laun, Alyssa S ^a   Song, Zhao Hui ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Cannabidiol; GPR3; GPR6; Inverse agonist; Orphan receptor; arrestin2

Indexed keywords

BETA ARRESTIN 2; CANNABICHROMENE; CANNABIDIOL; CANNABIGEROL; CANNABINOL; CANNABIS; ENDOCANNABINOID; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 3; G PROTEIN COUPLED RECEPTOR 6; TETRAHYDROCANNABINOL; UNCLASSIFIED DRUG; GPR3 PROTEIN, HUMAN; GPR6 PROTEIN, HUMAN;

ARTICLE; CONTROLLED STUDY; PRIORITY JOURNAL; PROTEIN TARGETING; AGONISTS; ANTAGONISTS AND INHIBITORS; HUMAN; INVERSE AGONISM; STRUCTURE ACTIVITY RELATION;

BETA-ARRESTIN 2; CANNABIDIOL; DRUG INVERSE AGONISM; HUMANS; RECEPTORS, G-PROTEIN-COUPLED; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 85020289313     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2017.05.165     Document Type: Article

References (38)

1. Eggerickx, D., Denef, J.F., Labbe, O., Hayashi, Y., Refetoff, S., Vassart, G., Parmentier, M., Libert, F., Molecular cloning of an orphan G-protein-coupled receptor that constitutively activates adenylate cyclase. Biochem. J. 309:Pt 3 (1995), 837–843.
2. Song, Z.H., Young, W.S. 3rd, Brownstein, M.J., Bonner, T.I., Molecular cloning of a novel candidate G protein-coupled receptor from rat brain. FEBS Lett. 351 (1994), 375–379.
3. Marchese, A., Docherty, J.M., Nguyen, T., Heiber, M., Cheng, R., Heng, H.H., Tsui, L.C., Shi, X., George, S.R., O'Dowd, B.F., Cloning of human genes encoding novel G protein-coupled receptors. Genomics 23 (1994), 609–618.
4. Song, Z.H., Modi, W., Bonner, T.I., Molecular cloning and chromosomal localization of human genes encoding three closely related G protein-coupled receptors. Genomics 28 (1995), 347–349.
5. Heiber, M., Docherty, J.M., Shah, G., Nguyen, T., Cheng, R., Heng, H.H., Marchese, A., Tsui, L.C., Shi, X., George, S.R., et al. Isolation of three novel human genes encoding G protein-coupled receptors. DNA Cell Biol. 14 (1995), 25–35.
6. Uhlenbrock, K., Gassenhuber, H., Kostenis, E., Sphingosine 1-phosphate is a ligand of the human gpr3, gpr6 and gpr12 family of constitutively active G protein-coupled receptors. Cell. Signal. 14 (2002), 941–953.
7. Martin, A.L., Steurer, M.A., Aronstam, R.S., Constitutive activity among orphan class-A G protein coupled receptors. PLoS One, 10, 2015, e0138463.
8. Prasad, B.M., Hollins, B., Lambert, N.A., Methods to detect cell surface expression and constitutive activity of GPR6. Methods Enzymol. 484 (2010), 179–195.
9. Valverde, O., Celerier, E., Baranyi, M., Vanderhaeghen, P., Maldonado, R., Sperlagh, B., Vassart, G., Ledent, C., GPR3 receptor, a novel actor in the emotional-like responses. PLoS One, 4, 2009, e4704.
10. Tourino, C., Valjent, E., Ruiz-Medina, J., Herve, D., Ledent, C., Valverde, O., The orphan receptor GPR3 modulates the early phases of cocaine reinforcement. Br. J. Pharmacol. 167 (2012), 892–904.
11. Ruiz-Medina, J., Ledent, C., Valverde, O., GPR3 orphan receptor is involved in neuropathic pain after peripheral nerve injury and regulates morphine-induced antinociception. Neuropharmacology 61 (2011), 43–50.
12. Lobo, M.K., Cui, Y., Ostlund, S.B., Balleine, B.W., Yang, X.W., Genetic control of instrumental conditioning by striatopallidal neuron-specific S1P receptor Gpr6. Nat. Neurosci. 10 (2007), 1395–1397.
13. Oeckl, P., Hengerer, B., Ferger, B., G-protein coupled receptor 6 deficiency alters striatal dopamine and cAMP concentrations and reduces dyskinesia in a mouse model of Parkinson's disease. Exp. Neurol. 257 (2014), 1–9.
14. Komatsu, H., Novel therapeutic GPCRs for psychiatric disorders. Int. J. Mol. Sci. 16 (2015), 14109–14121.
15. Tanaka, S., Ishii, K., Kasai, K., Yoon, S.O., Saeki, Y., Neural expression of G protein-coupled receptors GPR3, GPR6, and GPR12 up-regulates cyclic AMP levels and promotes neurite outgrowth. J. Biol. Chem. 282 (2007), 10506–10515.
16. Thathiah, A., Spittaels, K., Hoffmann, M., Staes, M., Cohen, A., Horre, K., Vanbrabant, M., Coun, F., Baekelandt, V., Delacourte, A., Fischer, D.F., Pollet, D., De Strooper, B., Merchiers, P., The orphan G protein-coupled receptor 3 modulates amyloid-beta peptide generation in neurons. Science 323 (2009), 946–951.
17. Benoit, M.E., Hernandez, M.X., Dinh, M.L., Benavente, F., Vasquez, O., Tenner, A.J., C1q-induced LRP1B and GPR6 proteins expressed early in Alzheimer disease mouse models, are essential for the C1q-mediated protection against amyloid-beta neurotoxicity. J. Biol. Chem. 288 (2013), 654–665.
18. Kostenis, E., Novel clusters of receptors for sphingosine-1-phosphate, sphingosylphosphorylcholine, and (lyso)-phosphatidic acid: new receptors for “old” ligands. J. Cell. Biochem. 92 (2004), 923–936.
19. Ignatov, A., Lintzel, J., Kreienkamp, H.J., Schaller, H.C., Sphingosine-1-phosphate is a high-affinity ligand for the G protein-coupled receptor GPR6 from mouse and induces intracellular Ca2+ release by activating the sphingosine-kinase pathway. Biochem. Biophys. Res. Commun. 311 (2003), 329–336.
20. Yin, H., Chu, A., Li, W., Wang, B., Shelton, F., Otero, F., Nguyen, D.G., Caldwell, J.S., Chen, Y.A., Lipid G protein-coupled receptor ligand identification using beta-arrestin PathHunter assay. J. Biol. Chem. 284 (2009), 12328–12338.
21. Lee, D.K., George, S.R., Evans, J.F., Lynch, K.R., O'Dowd, B.F., Orphan G protein-coupled receptors in the CNS. Curr. Opin. Pharmacol. 1 (2001), 31–39.
22. Pertwee, R.G., Ross, R.A., Cannabinoid receptors and their ligands. Prostagl. Leukot. Essent. Fat. Acids 66 (2002), 101–121.
23. Bassoni, D.L., Raab, W.J., Achacoso, P.L., Loh, C.Y., Wehrman, T.S., Measurements of beta-arrestin recruitment to activated seven transmembrane receptors using enzyme complementation. Methods Mol. Biol. 897 (2012), 181–203.
24. Porter, A.C., Sauer, J.M., Knierman, M.D., Becker, G.W., Berna, M.J., Bao, J., Nomikos, G.G., Carter, P., Bymaster, F.P., Leese, A.B., Felder, C.C., Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J. Pharmacol. Exp. Ther. 301 (2002), 1020–1024.
25. Hanus, L., Abu-Lafi, S., Fride, E., Breuer, A., Vogel, Z., Shalev, D.E., Kustanovich, I., Mechoulam, R., 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc. Natl. Acad. Sci. U. S. A. 98 (2001), 3662–3665.
26. Fezza, F., Bisogno, T., Minassi, A., Appendino, G., Mechoulam, R., Di Marzo, V., Noladin ether, a putative novel endocannabinoid: inactivation mechanisms and a sensitive method for its quantification in rat tissues. FEBS Lett. 513 (2002), 294–298.
27. Izzo, A.A., Borrelli, F., Capasso, R., Di Marzo, V., Mechoulam, R., Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol. Sci. 30 (2009), 515–527.
28. Zuardi, A.W., Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Rev. Bras. Psiquiatr. 30 (2008), 271–280.
29. Pertwee, R., The pharmacology and therapeutic potential of cannabidiol. Di Marzo, V., (eds.) Cannabinoids, 2004, 32–83.
30. Pertwee, R.G., The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br. J. Pharmacol. 153 (2008), 199–215.
31. Laprairie, R.B., Bagher, A.M., Kelly, M.E., Denovan-Wright, E.M., Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br. J. Pharmacol. 172 (2015), 4790–4805.
32. Russo, E.B., Burnett, A., Hall, B., Parker, K.K., Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem. Res. 30 (2005), 1037–1043.
33. Ryberg, E., Larsson, N., Sjogren, S., Hjorth, S., Hermansson, N.O., Leonova, J., Elebring, T., Nilsson, K., Drmota, T., Greasley, P.J., The orphan receptor GPR55 is a novel cannabinoid receptor. Br. J. Pharmacol. 152 (2007), 1092–1101.
34. Kathmann, M., Flau, K., Redmer, A., Trankle, C., Schlicker, E., Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors. Naunyn Schmiedeb. Arch. Pharmacol. 372 (2006), 354–361.
35. Thathiah, A., Horre, K., Snellinx, A., Vandewyer, E., Huang, Y., Ciesielska, M., De Kloe, G., Munck, S., De Strooper, B., Beta-arrestin 2 regulates Abeta generation and gamma-secretase activity in Alzheimer's disease. Nat. Med. 19 (2013), 43–49.
36. Garcia-Arencibia, M., Gonzalez, S., de Lago, E., Ramos, J.A., Mechoulam, R., Fernandez-Ruiz, J., Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties. Brain Res. 1134 (2007), 162–170.
37. Lastres-Becker, I., Molina-Holgado, F., Ramos, J.A., Mechoulam, R., Fernandez-Ruiz, J., Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease. Neurobiol. Dis. 19 (2005), 96–107.
38. Campos, A.C., Fogaca, M.V., Sonego, A.B., Guimaraes, F.S., Cannabidiol, neuroprotection and neuropsychiatric disorders. Pharmacol. Res. official J. Italian Pharmacol. Soc. 112 (2016), 119–127.